Tier-jumpers: Building the road to sustainable biotechs. Back to School 2023
How companies can build value and climb market cap tiers to reach the top
The market reset has been a healthy thing for biotech, according to almost everyone. Call it greed, call it investor FOMO, call it exuberance, call it divorce from reality, call it what you will, but the number of biotechs created in the past half-decade, and in many cases their valuations, were not underpinned by realistic potential for value creation.
So while companies living on fumes may not be pleased about it, there’s broad hope that this market-driven winnowing will leave the biotech ecosystem with a better crop of companies from which to build. ...